Filing a patent for a novel drug delivery system, especially in the chronic pain management sector, can be seen as a positive development for Silo Pharma. It not only showcases the company's commitment to innovation but also opens up potential new revenue streams if the patent is granted and the product reaches the market. Given the current interest in alternative pain management solutions, this move could attract investor interest and possibly lead to a short-term positive impact on SILO's stock price.